Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019

Similar Items

• Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies from 2015 – 2019
  od: Douglas, Michael P., i dr.
  Izdano: (2020)
• Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative
  od: Trosman, Julia R., i dr.
  Izdano: (2017)
• Health Technology Assessment and Private Payers' Coverage of Personalized Medicine
  od: Trosman, Julia R., i dr.
  Izdano: (2011)
• Perspectives of U.S. Private Payers on Insurance Coverage for Pediatric and Prenatal Exome Sequencing – Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS)
  od: Trosman, Julia R., i dr.
  Izdano: (2019)
• Challenges of Coverage Policy Development for Next-Generation Tumor Sequencing Panels: Experts and Payers Weigh In
  od: Trosman, Julia R., i dr.
  Izdano: (2015)